scholarly journals Epstein-Barr virus reactivation in a patient treated with anti-thymocyte globulin for severe aplastic anemia

2006 ◽  
Vol 81 (5) ◽  
pp. 355-357 ◽  
Author(s):  
Elisabetta Calistri ◽  
Mario Tiribelli ◽  
Marta Battista ◽  
Angela Michelutti ◽  
Mario Corbellino ◽  
...  
Keyword(s):  
Aplastic Anemia ◽  
Epstein Barr Virus ◽  
Severe Aplastic Anemia ◽  
Virus Reactivation ◽  
Barr Virus ◽  
Epstein Barr ◽  
Epstein Barr Virus Reactivation

scholarly journals Fatal Epstein-Barr Virus Reactivation in an Acquired Aplastic Anemia Patient Treated with Rabbit Antithymocyte Globulin and Cyclosporine A

2015 ◽  
Vol 2015 ◽  
pp. 1-4
Author(s):  
Tohru Takahashi ◽  
Yumiko Maruyama ◽  
Mayuko Saitoh ◽  
Hideto Itoh ◽  
Mitsuru Yoshimoto ◽  
...  
Keyword(s):  
Aplastic Anemia ◽  
Cyclosporine A ◽  
Peripheral Blood ◽  
Epstein Barr Virus ◽  
Virus Reactivation ◽  
Barr Virus ◽  
Peripheral Blood Plasma ◽  
Epstein Barr ◽  
High Level ◽  
Epstein Barr Virus Reactivation

Epstein-Barr virus (EBV) associated lymphoproliferative disorder (LPD) after immunosuppressive therapy for aplastic anemia (AA) is extremely rare in a nontransplant setting and has not been well described. This report describes a severe AA patient in whom fatal EBV-LPD developed after being treated with rabbit antithymocyte globulins (ATG) and cyclosporine A (CsA). An 81-year-old man was diagnosed as having severe AA. He was started on CsA followed by administration of ATG for five consecutive days. One month after the start of ATG, persistent fever which was not responsive to antibiotics or antifungal agents developed and atypical lymphocytes emerged in peripheral blood. Repeated blood cultures were negative. An extremely high level of EBV virus in his peripheral blood plasma was detected by means of a quantitative real-time PCR assay. Even after the cessation of CsA, the fever persisted and the peripheral atypical lymphocytes proliferated rapidly. The patient suffered from respiratory failure, liver dysfunction, and metabolic acidosis. Rituximab was administered without success and he died.

Valganciclovir suppressed Epstein Barr virus reactivation during immunosuppression with alemtuzumab

2014 ◽  
Vol 59 (4) ◽  
pp. 255-258 ◽  
Author(s):  
Harinder Gill ◽  
Yu-Yan Hwang ◽  
Thomas S.Y. Chan ◽  
Annie W.K. Pang ◽  
Anskar Y.H. Leung ◽  
...  
Keyword(s):  
Epstein Barr Virus ◽  
Virus Reactivation ◽  
Barr Virus ◽  
Epstein Barr ◽  
Epstein Barr Virus Reactivation

Successful outcome of severe aplastic anemia following epstein-barr virus infection

1988 ◽  
Vol 28 (4) ◽  
pp. 273-275 ◽  
Author(s):  
Judy E. Grishaber ◽  
Kenneth L. McClain ◽  
Donald H. Mahoney ◽  
Donald J. Fernbach
Keyword(s):  
Virus Infection ◽  
Aplastic Anemia ◽  
Epstein Barr Virus ◽  
Severe Aplastic Anemia ◽  
Successful Outcome ◽  
Epstein Barr Virus Infection ◽  
Barr Virus ◽  
Epstein Barr ◽  
Barr Virus Infection

OR10 Genetic predisposition to interleukin-10 production influences epstein-barr virus reactivation after renal transplantation

2015 ◽  
Vol 76 ◽  
pp. 21
Author(s):  
Gaurav Tripathi ◽  
Abdulnaser Abadi ◽  
Poonam Dharmani-Khan ◽  
Lee Anne Tibbles ◽  
Serdar Yilmaz ◽  
...  
Keyword(s):  
Renal Transplantation ◽  
Genetic Predisposition ◽  
Epstein Barr Virus ◽  
Interleukin 10 ◽  
Virus Reactivation ◽  
Barr Virus ◽  
Epstein Barr ◽  
Epstein Barr Virus Reactivation
Sign in / Sign up

Export Citation Format

Share Document